Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer

Author(s): Jiayu Sheng, Xiaohong Xue * and Ke Jiang*

Volume 19, Issue 2, 2019

Page: [147 - 155] Pages: 9

DOI: 10.2174/1566524019666190308122108

Price: $65

Abstract

Purpose: Breast cancer is the most prevalent malignancy and the leading cause of death among women. Triple-negative breast cancer (TNBC) is a subtype of breast cancer and shows a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared to other subtypes of breast cancer. This study aimed to assess the effect of KIF15 on various clinicopathological characteristics, survival analysis, and cell proliferation in triple-negative breast cancer, which has not been reported to our knowledge.

Methods: A total of 165 patients with triple-negative breast cancer were enrolled and clinical data were obtained, Mann-Whitney U analysis was performed to assess the correlation between the expression of KIF15 and clinical pathological characteristics of TNBC patients. Survival analysis was performed by Kaplan-Meier analysis and Log-rank test. The expression levels of KIF15 in cancer tissues and adjacent tissues were evaluated via Sign test. Lentivirus was used to down-regulate the expression of KIF15 in TNBC cells. The cell proliferation, colony formation capacity and apoptosis were examined by MTT, Giemsa staining and flow cytometry assay, respectively.

Results: Our results showed that, among the 165 TNBC patients, the expression of KIF15 was positive correlation with clinicopathological features of TNBC. In addition, KIF15 low-expression group showed higher disease-free survival than KIF15 highexpression group and univariate analysis showed that KIF15 high-expression group appeared higher mortality than KIF low-expression group (P ≤ 0.05). Meanwhile, the expression levels of KIF15 in cancer tissue notably up-regulated in comparison with adjacent tissue. In vitro, knockdown of KIF15 significantly promoted cell apoptosis and suppressed cell proliferation and colony formation of TNBC cells.

Conclusion: By utilizing survival analysis, we found that high-expression of KIF15 in the TNBC samples were associated with poorer overall survival, while the anti-tumor effect of KIF15 knockdown was also confirmed at the cellular level in vitro. Taken together, KIF15 can be applied as a potential diagnostic and therapeutic target in TNBC.

Keywords: TNBC, KIF15, survival analysis, apoptosis, proliferation, cancer cell.

« Previous Next »
[1]
Cedolini C, Bertozzi S, Londero AP, et al. Type of breast cancer diagnosis, screening, and survival. Clin Breast Cancer 2014; 14(4): 235-40.
[2]
Newman LA. Disparities in breast cancer and african ancestry: A global perspective. Breast J 2015; 21(2): 133-9.
[3]
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-52.
[4]
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-74.
[5]
Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355(6): 560-9.
[6]
Millis SZ, Gatalica Z, Winkler J, et al. Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer 2015; 15(6): 473-81.e3.
[7]
Jiao Q, Wu A, Shao G, et al. The latest progress in research on triple negative breast cancer (TNBC): Risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6(9): 1329-35.
[8]
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: Molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book 2015; e31-9.
[9]
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 2015; 121(1): 8-16.
[10]
Nowacka-Zawisza M, Krajewska WM. Triple-negative breast cancer: Molecular characteristics and potential therapeutic approaches. Postepy Hig Med Dosw (Online) 2013; 67: 1090-7.
[11]
Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017; 18(6): 369-78.
[12]
Bulatov E, Sayarova R, Mingaleeva R, et al. Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discov 2018; 4: 103.
[13]
Garmpis N, Damaskos C, Garmpi A, et al. Histone Deacetylases as new therapeutic targets in triple-negative breast cancer: Progress and promises. Cancer Genomics Proteomics 2017; 14(5): 299-313.
[14]
Khosravi-Shahi P, Cabezon-Gutierrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018; 14(1): 32-9.
[15]
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 2017; 389(10087): 2430-42.
[16]
Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: Insights into structure and function. Trends Cell Biol 2005; 15(9): 467-76.
[17]
Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998; 279(5350): 519-26.
[18]
Kitajima Y, Inoue S, Yoneda K, Mori S, Yaoita H. Alteration in the arrangement of the keratin-type intermediate filaments during mitosis in cultured human keratinocytes. Eur J Cell Biol 1985; 38(2): 219-25.
[19]
Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005; 16(7): 3187-99.
[20]
Appierto V, Tiberio P, Cavadini E, Casalini P, Cappelletti G, Formelli F. Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: A novel mechanism of retinoid growth-inhibitory activity. Mol Cancer Ther 2009; 8(12): 3360-8.
[21]
Liu X, Gong H, Huang K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci 2013; 104(6): 651-6.
[22]
Duan H, Zhang X, Wang FX, et al. KIF-2C expression is correlated with poor prognosis of operable esophageal squamous cell carcinoma male patients. Oncotarget 2016; 7(49): 80493-507.
[23]
Taniwaki M, Takano A, Ishikawa N, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007; 13(22 Pt 1): 6624-31.
[24]
Narayan G, Bourdon V, Chaganti S, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007; 46(4): 373-84.
[25]
Zou JX, Duan Z, Wang J, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res 2014; 12(4): 539-49.
[26]
Wang J, Guo X, Xie C, Jiang J. KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. Br J Cancer 2017; 117(2): 245-55.
[27]
Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K. Angiopoietin pathway gene expression associated with poor breast cancer survival. Breast Cancer Res Treat 2017; 162(1): 191-8.
[28]
Zeinalian M, Emami MH, Naimi A, Salehi R, Hashemzadeh-Chaleshtori M. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome. Iran J Cancer Prev 2015; 8(1): 11-7.
[29]
Juszczak K, Kaszuba-Zwoinska J, Thor PJ. Pulsating electromagnetic field stimulation of urothelial cells induces apoptosis and diminishes necrosis: new insight to magnetic therapy in urology. J Physiol Pharmacol 2012; 63(4): 397-401.
[30]
Palma G, Frasci G, Chirico A, et al. Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget 2015; 6(29): 26560-74.
[31]
Gautam P, Karhinen L, Szwajda A, et al. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Mol Cancer 2016; 15(1): 34.
[32]
Proia DA, Zhang C, Sequeira M, et al. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res 2014; 20(2): 413-24.
[33]
Yu Y, Feng YM. The role of kinesin family proteins in tumorigenesis and progression: Potential biomarkers and molecular targets for cancer therapy. Cancer 2010; 116(22): 5150-60.
[34]
Amy MB, Rachel VS, Jessica ME, Adedayo AO. Breast cancer biomarkers: Risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des 2014; 20(30): 4879-98.
[35]
Qiao Y, Chen J, Ma C, et al. Increased KIF15 expression predicts a poor prognosis in patients with lung Adenocarcinoma. Cell Physiol Biochem 2018; 51(1): 1-10.
[36]
Zhou J, Chen WR, Yang LC, et al. KIF11 functions as an oncogene and is associated with poor outcomes from breast cancer. Cancer Res Treat 2018. [Epub ahead of print].
[http://dx.doi.org/10.4143/crt.2018.460]
[37]
Wang J, Guo X, Xie C, Jiang J. KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. Br J Cancer 2017; 117(2): 245-55.

Rights & Permissions Print Cite
Article Metrics
80
6
2
1
World Malaria Day
© 2024 Bentham Science Publishers | Privacy Policy